reslizumab
Res-5-0004
Phase 3 small_molecule completed
Quick answer
reslizumab for Eosinophilic Esophagitis is a Phase 3 program (small_molecule) at TEVA PHARMACEUTICAL INDUSTRIES LTD with 2 ClinicalTrials.gov record(s).
Program details
- Company
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Indication
- Eosinophilic Esophagitis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed